Elevian

Elevian

  • Founded: 2017
  • Location: Allston, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin0
  • Therapy area: Ischemic stroke
  • Drug types: CVV, NEU, X_X, HEP
  • Lead product: ELV-001
  • Product link: https://www.elevian.com/elevian-science
  • Funding: $40M A Sep 2021; $5.5M seed Sep 2018


elevian.com

linkedin.com

job board


Short description:

Blood components to fight aging

Drug notes:

Also Clin0 hemorrhagic stroke, RD ischemic recovery/limb ischemia, RD inflammation/pancreatitis; ELV-002 RD wound healing; ELV-003 RD cardiometabolic & inflammatory conditions; ELV-101 RD cardiometabolic & inflammatory conditions

Long description:

Elevian is focusing on generating recombinant proteins to facilitate recovery and regeneration. Stroke is a debilitating disease with around 15 million people suffering from strokes each year. Currently, there are no therapies available that can offer recovery within the first hours to days following the stroke. Elevian is developing a recombinant protein called rGDF11 that has previously been shown to facilitate motor function recovery in animal models of both ischemic and hemorrhagic stroke. It is thought that this is because of rGDF11s ability to promote neovascularization. However, Elevian foresees beneficial effects of rGDF11 beyond stroke and are looking to apply their approach to other age-associated diseases.

Jobs:


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com